<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264625</url>
  </required_header>
  <id_info>
    <org_study_id>Vitamin D, RCT</org_study_id>
    <nct_id>NCT03264625</nct_id>
  </id_info>
  <brief_title>The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis</brief_title>
  <official_title>The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot randomized, controlled trial of Vitamin D supplementation in patients on&#xD;
      peritoneal dialysis to determine the feasibility of a future full-scale RCT exploring if oral&#xD;
      administration of vitamin D3 could reduce the risk of subsequent Peritoneal dialysis-related&#xD;
      (PD-related) peritonitis.&#xD;
&#xD;
      Aims of the study:&#xD;
&#xD;
      Aim 1: To determine the feasibility of oral vitamin D supplementation among PD patients who&#xD;
      have recovered from a recent episode of peritonitis.&#xD;
&#xD;
      Aim 2: To examine the effect of vitamin D supplementation on the risk for peritonitis among&#xD;
      patients on peritoneal dialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be screened for eligibility one month after the onset of PD-related&#xD;
      peritonitis, those who meet the inclusion criteria will be enrolled in this study.&#xD;
&#xD;
      All consenting participants will be randomized into the vitamin D treatment group or the&#xD;
      control group, general information and baseline biochemistry data would be collected.&#xD;
      Patients in the treatment group will be treated with oral Cholecalciferol (2000IU/day) apart&#xD;
      from routine treatment for PD. Those in the control group will receive routine treatment for&#xD;
      PD. Both groups will be followed for 12 months. During the observational period, any onset of&#xD;
      subsequent peritonitis will be recorded, serum 25(OH)D, biochemical indices will be measured&#xD;
      every 3 months. Follow up would take place frequently, any outcome events would be recorded.&#xD;
&#xD;
      Aims and hypotheses:&#xD;
&#xD;
      Aim 1: To determine the feasibility of oral vitamin D supplementation among PD patients who&#xD;
      have recovered from a recent episode of peritonitis.&#xD;
&#xD;
      Hypothesis1: A large、full-scale randomized controlled trail on the effects of oral vitamin D&#xD;
      on the risk for peritonitis among PD patients is feasible.&#xD;
&#xD;
      Aim 2: To examine the effect of vitamin D supplementation on the risk for peritonitis among&#xD;
      patients on peritoneal dialysis.&#xD;
&#xD;
      Hypothesis 2: Oral supplementation of vitamin D will reduce the risk of subsequent peritoneal&#xD;
      dialysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2017</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate of the trial</measure>
    <time_frame>From date of randomization until 1 year after the randomization of last participant.</time_frame>
    <description>Recruitment rate of patients screened for the trial measured by percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention rate of the trial</measure>
    <time_frame>From date of randomization until 1 year after the randomization of last participant</time_frame>
    <description>Retention rate of included patients in the trial measured by percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence rate of the trial</measure>
    <time_frame>From date of randomization until 1 year after the randomization of last participant.</time_frame>
    <description>Percentage of participants adherent to the dosing regimen of vitamin D in the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From date of randomization until 1 year after the randomization of last participant.</time_frame>
    <description>Incidence of adverse events measured by number of events per patient-month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum 25(OH)D level</measure>
    <time_frame>From date of randomization until 1 year after the randomization of last participant</time_frame>
    <description>Change in serum 25(OH)D level between baseline and 12 months measured by ng/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in risk of a subsequent peritonitis measured by Hazard Ratio.</measure>
    <time_frame>From date of randomization until the date of subsequent peritonitis, assessed up to 1 year.</time_frame>
    <description>Risk of a subsequent peritoneal dialysis related peritonitis in the interventional group compared with the control group measured by Hazard Ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of participants who recovered after subsequent peritoneal dialysis related peritonitis.</measure>
    <time_frame>From date of randomization until the date of documented death, assessed up to 1 year.</time_frame>
    <description>Probability of participants who recovered after peritoneal dialysis-related peritonitis measured by percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of participants who died because of subsequent peritoneal dialysis related peritonitis.</measure>
    <time_frame>From date of randomization until the date of documented death, assessed up to 1 year.</time_frame>
    <description>Risk of participants who died because of peritoneal dialysis-related peritonitis measured by percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of participants who are transitioned to hemodialysis because of subsequent peritoneal dialysis related peritonitis.</measure>
    <time_frame>From date of randomization until the date of documented transition to hemodialysis because of peritoneal dialysis related peritonitis, assessed up to 1 year.</time_frame>
    <description>Risk of patients who are transferred to hemodialysis because of peritoneal dialysis related peritonitis measured by percentage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peritoneal Dialysis-associated Peritonitis</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the placebo group will receive routine therapy for PD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol (2000iu qd)</intervention_name>
    <description>Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Natural Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine therapy for PD</intervention_name>
    <description>Patients randomized to the placebo group will receive routine therapy for PD.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Medically stable and receiving peritoneal dialysis (PD) for&gt;1 months&#xD;
&#xD;
          2. Age at least 18 years.&#xD;
&#xD;
          3. Serum 25(OH)D&lt;75nmol/l (30ng/ml)&#xD;
&#xD;
          4. Adequate dialysis on evaluation, weekly Kt/V ≥ 1.5 and no clinical uremic symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receive Vitamin D2/D3 or drugs known to alter serum 25-hydroxyvitamin D (25(OH)D)&#xD;
             levels during the previous 12 months;&#xD;
&#xD;
          2. History of allergic reaction to Cholecalciferol;&#xD;
&#xD;
          3. Current or past malignant disease, active hepatitis or hepatic failure, acute systemic&#xD;
             infection, active autoimmune diseases, severe digestive malabsorption or eating&#xD;
             disorder, HIV/AIDS;&#xD;
&#xD;
          4. A high probability (assessed by the recruiting physician) of receiving a kidney&#xD;
             transplant or transferring to hemodialysis (HD) or drop-out due to socioeconomic&#xD;
             causes within 6 months;&#xD;
&#xD;
          5. Pregnant or breastfeeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Dong</last_name>
    <role>Study Director</role>
    <affiliation>Peking Universiy First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pi HC, Ren YP, Wang Q, Xu R, Dong J. Serum 25-Hydroxyvitamin D Level Could Predict the Risk for Peritoneal Dialysis-Associated Peritonitis. Perit Dial Int. 2015 Dec;35(7):729-35. doi: 10.3747/pdi.2014.00177. Epub 2015 Jul 29.</citation>
    <PMID>26224791</PMID>
  </reference>
  <reference>
    <citation>Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R. 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol. 2012 Sep;7(9):1428-34. doi: 10.2215/CJN.12761211. Epub 2012 Jul 12.</citation>
    <PMID>22798536</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong Jie</investigator_full_name>
    <investigator_title>Director of PD center</investigator_title>
  </responsible_party>
  <keyword>Cholecalciferol</keyword>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Peritonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03264625/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

